Boehringer Ingelheim and Lilly Commence P-III EMPULSE Study to Evaluate Jardiance in People Hospitalized for Acute Heart Failure Who Have Been Stabilized

 Boehringer Ingelheim and Lilly Commence P-III EMPULSE Study to Evaluate Jardiance in People Hospitalized for Acute Heart Failure Who Have Been Stabilized

Boehringer Ingelheim and Lilly Commence P-III EMPULSE Study to Evaluate Jardiance in People Hospitalized for Acute Heart Failure Who Have Been Stabilized

Shots:

  • The P-III EMPLULSE study (NCT04157751) will evaluate clinical benefits safety and tolerability of Jardiance (empagliflozin, 10mg, PO) in ~500 patients hospitalized for acute heart failure who have been stabilized including patients both with and without T2D
  • The P-III EMPULSE study will evaluate whether Jardiance will able alleviate symptoms associated with HF and improve outcomes after discharge from the hospital with 1EPs as net clinical benefit, a composite of all-cause mortality, number of heart failure events, time to first heart failure event and change from baseline in KCCQ-CSS
  • Jardiance (empagliflozin, qd) is an oral therapy used to lower the blood sugar level in adults with T2D and cardiovascular diseases and is contraindicated in patients with T1D and diabetic ketoacidosis

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Livemint

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post